Literature DB >> 12871750

Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors.

Yvette V Ugarte1, Kristi S Rau, Evan L Riddle, Glen R Hanson, Annette E Fleckenstein.   

Abstract

Multiple high-dose administrations of the dopamine-releasing agent, methamphetamine, rapidly and persistently decrease vesicular dopamine uptake in purified vesicles prepared from striata of treated rats. Because important differences in the neurotoxic effects of stimulants have been documented in rats and mice, the purpose of this study was to determine if methamphetamine-induced effects in rats occur in mice and to elucidate mechanisms underlying these effects. Results reveal methamphetamine treatment rapidly decreased mouse striatal vesicular dopamine uptake; a phenomenon associated with a subcellular redistribution of vesicular monoamine transporter-2 (VMAT-2) immunoreactivity. Both methamphetamine-induced hyperthermia and dopamine D2 receptor activation contributed to the stimulant-induced deficits in vesicular dopamine uptake. Unlike methamphetamine, the dopamine reuptake inhibitors, methylphenidate and cocaine, rapidly increased vesicular dopamine uptake. The implications of these phenomena are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871750     DOI: 10.1016/s0014-2999(03)01911-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Electroencephalographic and convulsive effects of binge doses of (+)-methamphetamine, 5-methoxydiisopropyltryptamine, and (±)-3,4-methylenedioxymethamphetamine in rats.

Authors:  Devon L Graham; Nicole R Herring; Tori L Schaefer; Katherine D Holland; Charles V Vorhees; Michael T Williams
Journal:  Open Neuropsychopharmacol J       Date:  2012

2.  Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.

Authors:  Kelly M Lohr; Kristen A Stout; Amy R Dunn; Minzheng Wang; Ali Salahpour; Thomas S Guillot; Gary W Miller
Journal:  ACS Chem Neurosci       Date:  2015-03-09       Impact factor: 4.418

3.  Comparison of (+)-methamphetamine, ±-methylenedioxymethamphetamine, (+)-amphetamine and ±-fenfluramine in rats on egocentric learning in the Cincinnati water maze.

Authors:  Charles V Vorhees; Elizabeth He; Matthew R Skelton; Devon L Graham; Tori L Schaefer; Curtis E Grace; Amanda A Braun; Robyn Amos-Kroohs; Michael T Williams
Journal:  Synapse       Date:  2010-10-08       Impact factor: 2.562

4.  The Role of Biogenic Amine Transporters in Trace Amine-Associated Receptor 1 Regulation of Methamphetamine-Induced Neurotoxicity.

Authors:  Nicholas B Miner; Tamara J Phillips; Aaron Janowsky
Journal:  J Pharmacol Exp Ther       Date:  2019-07-18       Impact factor: 4.030

Review 5.  Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.

Authors:  Kandatege Wimalasena
Journal:  Med Res Rev       Date:  2010-02-04       Impact factor: 12.944

6.  Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).

Authors:  Ashish P Vartak; Justin R Nickell; Jaturaporn Chagkutip; Linda P Dwoskin; Peter A Crooks
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

7.  PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.

Authors:  T S Guillot; J R Richardson; M Z Wang; Y J Li; T N Taylor; B J Ciliax; O Zachrisson; A Mercer; G W Miller
Journal:  Neuropeptides       Date:  2008-06-03       Impact factor: 3.286

8.  GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs.

Authors:  Daniela Marazziti; Silvia Mandillo; Chiara Di Pietro; Elisabetta Golini; Rafaele Matteoni; Glauco P Tocchini-Valentini
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-22       Impact factor: 11.205

9.  Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis.

Authors:  Thomas S Guillot; Kennie R Shepherd; Jason R Richardson; Min Z Wang; Yingjie Li; Piers C Emson; Gary W Miller
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

Review 10.  Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.

Authors:  Thomas S Guillot; Gary W Miller
Journal:  Mol Neurobiol       Date:  2009-03-04       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.